

Risdiplam Listing 1 August 2021

Spinal Muscular Atrophy Australia Inc. (SMA Australia) are extremely excited to advise the SMA community that Risdiplam has been announced for funding today from the Minister for Health Hon Greg Hunt. The listing includes Type 1, 2 and 3 for those under the age of 18.

This announcement is another fantastic step forward for the treatment choice of families living with SMA. Families are now able to liaise with their clinicians to determine the best option for their family.

The SMA treatment space has rapidly changed in the past 5 years with no treatment available to now 2 treatment options for families. This is another huge milestone in the landscape of SMA.

Disappointingly, the treatment needs of the SMA population over the age of 18 remain unmet. SMA Australia realise this part of our community will be devastated. Due to the infancy of the drug, and lack of robust clinical data in the adult population, the PBAC was unable to assess the extent of the meaningful benefit the drug may have on the adult population.

SMA Australia will continue to work closely with the PBAC to identify what further information is required for the adult population and we will be calling on you in the future to assist us in gathering this information. We are also working alongside Roche to gather the required data and real world evidence that they may require for any future PBAC submissions.

If you have any questions please do not hesitate to email me at smaa@smaaustralia.org.au

Kind Regards



Julie Cini